Ivonescimab is an experimental drug given by IV infusion. It is a type of antibody that is being studied to see if it can help the immune system recognize and attack cancer cells. In this trial it is combined with other medicines to test its safety and how well it works.
Cetuximab (sold as Erbitux) is an approved medicine that blocks a protein called EGFR on cancer cells. By stopping EGFR, it can slow the growth of some tumors. In the study it is used together with ivonescimab to see if the two drugs work better together.
Cisplatin is a chemotherapy drug given through an IV solution. It works by damaging the DNA of cancer cells, which can stop them from growing. In this trial it may be added to the combination of ivonescimab and other agents to see how the mix is tolerated.
Carboplatin is another chemotherapy medicine delivered by IV infusion. Like cisplatin, it interferes with the DNA of cancer cells to stop their growth. It is being tested in combination with ivonescimab and other study drugs.
Pemetrexed is a chemotherapy drug that is given as an IV infusion. It stops cancer cells from making the building blocks they need to multiply. In the trial it may be used alongside ivonescimab and other treatments.
RMC-6291 is an oral, experimental medication that targets the active form of the RAS protein inside cancer cells. By blocking this protein, the drug aims to stop tumor growth. The study is looking at how safe it is and what dose works best when combined with ivonescimab.
RMC-6236 (also called DARAXONRASIB) is an oral investigational drug designed to inhibit the “ON” state of the RAS protein, which drives many cancers. It is being tested with ivonescimab to find a safe dose and see if the combination can control tumor growth.
RMC-9805 is an oral experimental therapy whose exact mechanism is being studied. It is included in the trial to evaluate its safety and potential benefit when given with ivonescimab and possibly other anti‑cancer agents.